PURPOSE To discuss the predisposing risk factor for all forms of extramedullary leukemia
(EML) and to review the clinical features, prognostic significance, and treatment strategies …

We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction
chemotherapy in an effort to improve remission durations for patients with acute …

Clinical trails conducted in the People's Republic of china and the United States of the
antileukemic efficacy of the cephalotaxine esters are reviewed. Harringtonine has been …

The lengthening remission duration achievable in acute myelogenous leukemia (AML)
places patients at risks for CNS leukemic relapse. We reviewed the data on two Eastern …

High-dose (HD) cytosine arabinoside (ARA-C) is more effective treatment than conventional-
dose ARA-C regimens for patients with relapsed acute nonlymphocytic leukemia (ANLL) …

• The use of immunotherapy for acute myelogenous leukemia (AML) is controversial. Twenty-
four trials have been reported in which 1,491 patients with AML received various forms of …

Between 1977 and 1983, symptomatic meningeal leukemia was diagnosed in 9 of 93 adult
patients with acute nonlymphocytic leukemia (10%). All cases occurred after complete …

In an attempt to rationalize the use of therapy in acute myeloblastic leukemia (AML) in
elderly patients, 69 cases of primary AML in patients older than 60 years of age were …

During the past decade, combination anthracycline and cytarabine chemotherapy,
sometimes accompanied by 6-thioguanine, has been associated with an increase in the …

Short-term treatment with doxorubicin, cytarabine, and 6-thioguanine was given to 91
consecutive adults with acute myelogenous leukaemia. Fifty patients received high doses …